Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on uniQure BV (NASDAQ: QURE).The analyst comments "FDA ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

Cantor Fitzgerald Upgrades uniQure BV (QURE) to OverweightJune 17, 2026 11:49 AM Biotech's New Frontier: Companies Breaking Through Medicine's Toughest BarriersJune 17, 2026 10:38 AM uniQure BV (QURE) PT Raised to $71 at StifelJune 17, 2026 9:31 AM Barclays Comments on uniQure BV (QURE) Amid 66% Gain: 'a major positive'June 17, 2026 9:11 AM uniQure (QURE) to resume trading at 7:35 a.m.June 17, 2026 7:22 AM ClearPoint Neuro stock surges on peer's FDA approval planJune 17, 2026 7:21 AM Form 8-K uniQure N.V. For: Jun 17June 17, 2026 7:11 AM uniQure plans BLA submission for Huntington's therapy in Q3 2026June 17, 2026 7:06 AM uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s DiseaseJune 17, 2026 7:05 AM Form 8-K uniQure N.V. For: Jun 10June 15, 2026 4:31 PM